Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Current Assets (2016 - 2025)

Viridian Therapeutics, Inc.\DE (VRDN) has 12 years of Current Assets data on record, last reported at $571.9 million in Q3 2025.

  • For Q3 2025, Current Assets fell 25.47% year-over-year to $571.9 million; the TTM value through Sep 2025 reached $571.9 million, down 25.47%, while the annual FY2024 figure was $738.5 million, 51.8% up from the prior year.
  • Current Assets reached $571.9 million in Q3 2025 per VRDN's latest filing, down from $738.5 million in the prior quarter.
  • Across five years, Current Assets topped out at $767.4 million in Q3 2024 and bottomed at $115.5 million in Q2 2021.
  • Average Current Assets over 5 years is $382.1 million, with a median of $364.5 million recorded in 2023.
  • Peak YoY movement for Current Assets: surged 581.66% in 2021, then decreased 25.96% in 2023.
  • A 5-year view of Current Assets shows it stood at $200.2 million in 2021, then skyrocketed by 115.41% to $431.2 million in 2022, then increased by 12.83% to $486.5 million in 2023, then soared by 51.8% to $738.5 million in 2024, then fell by 22.55% to $571.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Current Assets were $571.9 million in Q3 2025, $738.5 million in Q4 2024, and $767.4 million in Q3 2024.